INSMED Inc (INSM) Form 10-Q — Aug 6, 2026
Insmed reported total product revenues of $731.5 million for the six months ended June 30, 2026, a 265% increase from the prior year period driven by $515.7 million in US commercial sales of BRINSUPRI following its August 2025 approval. The company incurred a net loss of $176.8 million and used $311.6 million in cash from operating activities, partially offset by $290.0 million in cash from investing activities related to marketable securities maturities. As of June 30, 2026, Insmed held $544.8 million in cash and cash equivalents and $615.5 million in marketable securities, which management believes will fund operations for at least the next 12 months.
Key figures
- Revenue
- 731450
- Total Debt
- 543513
- Revenue Yoy
- 265
- Total Assets
- 2102565
- Cash Position
- 544765
- Shares Outstanding
- 218281059
- Debt Maturity
- 2029
- Brinsupri Revenue
- 517024
- Debt Interest Rate
- 9.6
- Term Loans Principal
- 500000
- Marketable Securities
- 615547
- Contingent Consideration
- 170550
- Royalty Financing Liability
- 159843
Price after filing
Close on the filing date to close N calendar days later (from $98.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.